April 2022, Vol 13, No 2

Community-based providers remain at the core of the oncology care delivery system. A panel moderated by Barbara McAneny, MD, Chief Executive Officer, New Mexico Oncology Hematology Consultants, Albuquerque, at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021 explored the road ahead for community practices in terms of balancing value and delivering optimal access to care for patients.
Read More

The antibody–drug conjugate pol­atuzumab vedotin-piiq (Polivy) added to R-CHP (rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) achieved a 27% reduction in the risk for progression or death compared with the standard regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line therapy for patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL).
Read More

Interim results from a phase 2 clinical trial showed that a novel combination of aldoxorubicin, N-803 (an IL-15 super­agonist), and PD-L1 natural killer cell therapy (Nant Cancer Vaccine) plus low-dose chemotherapy doubled overall survival (OS) compared with historical controls in patients with locally advanced or metastatic pancreatic cancer.
Read More

With better insights into the biology of cancer and other diseases, genetic medicine is entering “a whole new ballgame,” said Scott Gottlieb, MD, Former FDA Commissioner, during the keynote session at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021.
Read More

Page 3 of 3